drugset / Trial / NCT01451632
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study was to evaluate the safety and tolerability of escalating doses of the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.
Timeline
- Start
- 2011-10
- Primary completion
- 2013-11
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | — | Intravenous |
| Subject | Irinotecan | Small molecule | 180 mg/m2 | Intravenous |
| Subject | Seribantumab | Monoclonal antibody | — | Intravenous |